These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32690723)

  • 1. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
    Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
    Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
    Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
    Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
    Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
    Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
    Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
    Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
    Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
    Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
    Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
    Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening.
    Zhang J; Shen L; Johnston SA
    Sci Rep; 2018 Nov; 8(1):17366. PubMed ID: 30478295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.
    Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M
    Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
    Bauer K; Nelius N; Reuschenbach M; Koch M; Weitz J; Steinert G; Kopitz J; Beckhove P; Tariverdian M; von Knebel Doeberitz M; Kloor M
    Cancer Immunol Immunother; 2013 Jan; 62(1):27-37. PubMed ID: 22729559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Biology of Microsatellite-Unstable Cancer.
    Kloor M; von Knebel Doeberitz M
    Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
    Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
    Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].
    Kloor M
    Pathologe; 2013 Nov; 34 Suppl 2():277-81. PubMed ID: 24196629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.
    Garbe Y; Maletzki C; Linnebacher M
    PLoS One; 2011; 6(11):e26517. PubMed ID: 22110587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.
    Roudko V; Bozkus CC; Orfanelli T; McClain CB; Carr C; O'Donnell T; Chakraborty L; Samstein R; Huang KL; Blank SV; Greenbaum B; Bhardwaj N
    Cell; 2020 Dec; 183(6):1634-1649.e17. PubMed ID: 33259803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO).
    Linnebacher M; Wienck A; Boeck I; Klar E
    J Biomed Biotechnol; 2010; 2010():841451. PubMed ID: 20339516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
    D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
    Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.